Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT for Valeant Pharmaceuticals International

Share:
Related VRX
Morgan Stanley Reiterates Overweight, Raises Price Target On Valeant Pharmaceuticals On New Proforma Model For SLXP
Here's Why CRT Capital Boosted Valeant Pharmaceuticals' Price Target
Jazz Pharmaceuticals Tops Q4 Earnings And Tests Buy Point (Investor's Business Daily)

In a report published earlier today, Jefferies & Company, Inc. reiterated its Buy rating for Valeant Pharmaceuticals International, Inc. (NYSE: VRX), but lowered its price target from $75.00 to $63.00.

Jefferies went on to say “After what we viewed as an excellent analyst day yesterday, VRX remains controversial ... yet an excellent investment -- especially after yesterday's weakness. For a company with >20% exposure in Europe, to actually reaffirm the UPPER end of its EPS guidance is a testament to the strength and durability of its business model. We now lower our PT for a more realistic market.”

Valeant Pharmaceuticals International, Inc. closed yesterday at $45.23.

Latest Ratings for VRX

DateFirmActionFromTo
Feb 2015Morgan StanleyMaintainsOverweight
Feb 2015BarclaysMaintainsOverweight
Feb 2015Stifel NicolausMaintainsBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Jefferies & Company Inc.Analyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (VRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters